Amping up T cells to target cancer
Vaccines that turn the body’s immune system against tumors have shown promise in clinical trials, and a handful have been FDA approved for certain cancers. In many patients, however, these vaccines don’t stimulate enough of a response, and the approach some researchers have taken to strengthening it—delivering the vaccine along with immune-stimulating molecules called cytokines—can…
MIT Technology Review
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from MIT Technology Review.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
MIT Technology ReviewTier B
Amping up T cells to target cancer(opens original report in a new tab)
How CurrentWire compiled this story
MIT Technology Review (www.technologyreview.com), a Tier B publisher, filed this report on . CurrentWire published this page 30 minutes later, on .
Signal breakdown
CurrentWire ranked this story 65 of 100 in the snapshot this page was rendered from.
- Freshness
- 33.5 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 3.5 of 10
- Velocity
- 0 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Health · United States · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: FDA (4).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.